Genmab — Maj 2019
-
@sukkeralf. Nej kursmæssigt har sc ikke rykket noget (endnu). Men det har de andre studie-nyheder heller ikke siden efteråret. Det eneste, der reelt har kunnet mærkes på kursen var 3-mia-guidningen. Alt andet har været den ene lange næse efter den anden. Belært heraf forventer jeg mig heller ikke noget af Maia-godkendelse - kun te og kiks.
-
En god fredagsnyhed vil være en perfekt optakt til mandagens Q&A. Her kan vi godt bruge flere spørgsmål.
-
Synes det er en kæmpe overreaktion på Ambu. Skulle deres produkter blive ringere bare fordi de skifter topchef. ?? Den kommer snart derop igen. Genmab fortsætter også bare lidt tilbage og lidt frem. Lidt fattigere på papiret, men fortrøstningsfuld. God weekend fra små 30 gr på Solkysten.
-
enig bibob 16.56. Produkter, know-how og medarbejderstaben er intakt, at så ham der uddelegerer arbejdet til andre forsvinder, kan på ingen måde berettige et kursfald af den størrelsesorden vi har set i dag. Lidt det samme skete i Demant, da den overvurderede Lars Kolind smed tøjlerne.
-
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. "The initiation of our first phase 3 trial represents another important milestone in advancing MOR202/TJ202 towards registration with the hope of providing more therapeutic options for multiple myeloma patients globally. Under I-Mab's fast-to-market development strategy, the phase 3 study, if successful, could lead to a biologics license application (BLA) in Greater China.
Yahoo Finance (finance.yahoo.com)
Tak for fin opsummering/gennemgang af GENs situation pt. samt nye stoffer/potentialer.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind